Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$1.42 USD
-0.02 (-1.39%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.42 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMCheckpoint Therapeutics, Inc. (CKPT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.25 | $34.00 | $4.00 | 1,167.36% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Checkpoint Therapeutics, Inc. comes to $18.25. The forecasts range from a low of $4.00 to a high of $34.00. The average price target represents an increase of 1% from the last closing price of $1.44.
Analyst Price Targets (4 )
Broker Rating
Checkpoint Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/2/2024 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Strong Buy |
4/2/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
3/22/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
8/16/2023 | Lake Street Capital Markets | Thomas Flaten | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $18.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.37 |